{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T18:32:45Z","timestamp":1769625165550,"version":"3.49.0"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:p>Objective. To explore pharmacokinetic factors underlying the poor bacteriologic eradication rate with a single 500-mg dose of ceftriaxone for streptococcal tonsillopharyngitis and to identify the minimum ceftriaxone dose required for effective treatment.<\/jats:p>\n               <jats:p>Methods. Population modeling techniques were applied to pharmacokinetic data derived from paired plasma and tonsil samples from 153 children to assess the contribution of pharmacokinetic variability to patients' responses to ceftriaxone. In addition, a Monte Carlo simulation was performed to determine (1) the amount of time that free ceftriaxone concentrations must exceed the minimum inhibitory concentration (MIC) of group A Streptococcus to achieve bacteriologic eradication and (2) the ceftriaxone dose required to maintain free drug concentrations above the target MIC for the requisite amount of time. Ceftriaxone MICs for group A Streptococcus were obtained from a previous trial, in which all MICs (n = 115) were \u22640.064 mg\/L; 33.9% were susceptible at \u22640.016 mg\/L, 66.4% were susceptible at 0.032 mg\/L, and 1.7% were susceptible at 0.064 mg\/L.<\/jats:p>\n               <jats:p>Results. Mean population pharmacokinetic parameters and their variances reflected substantial variability of clearance and half-life in the target population. Tonsillar ceftriaxone protein binding was 89.1%. The proportions of 1000 simulated patients with free ceftriaxone concentrations that exceeded MICs of 0.016 mg\/L, 0.032 mg\/L, and 0.064 mg\/L at 24 hours were 71.7%, 65.4%, and 57.2%, respectively, and at 48 hours were 41.8%, 35.8%, and 28.6%, respectively. The amount of time that free ceftriaxone concentrations need to exceed MIC to achieve bacteriologic success was estimated to be 36 hours. Using this time criterion, two 500-mg doses of ceftriaxone separated by 18 hours should achieve a bacteriologic cure rate of \u223c95%.<\/jats:p>\n               <jats:p>Conclusions. Pharmacokinetic variability and high ceftriaxone tonsillar protein binding explain the high microbiologic failure rate for a single 500-mg dose of ceftriaxone in group A streptococcal tonsillopharyngitis. Monte Carlo simulation suggests that a second dose administered 18 hours after the first will be required to achieve an acceptable bacteriologic cure rate.<\/jats:p>","DOI":"10.1542\/peds.2004-2294","type":"journal-article","created":{"date-parts":[[2005,9,30]],"date-time":"2005-09-30T18:42:55Z","timestamp":1128105775000},"page":"927-932","source":"Crossref","is-referenced-by-count":33,"title":["Explaining the Poor Bacteriologic Eradication Rate of Single-Dose Ceftriaxone in Group A Streptococcal Tonsillopharyngitis: A Reverse Engineering Solution Using Pharmacodynamic Modeling"],"prefix":"10.1542","volume":"116","author":[{"given":"Jeffrey L.","family":"Blumer","sequence":"first","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Reed","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"},{"name":"Pharmacology, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward L.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George L.","family":"Drusano","sequence":"additional","affiliation":[{"name":"Ordway Research Institute and New York State Department of Health, Albany, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2005,10,1]]},"reference":[{"key":"2021120819510945400_R1","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Casey JR, Mayes T, et al. Penicillin failure in streptococcal tonsillopharyngitis: causes and remedies. Pediatr Infect Dis J.\u20082000;19:917\u2013923","DOI":"10.1097\/00006454-200009000-00035"},{"key":"2021120819510945400_R2","doi-asserted-by":"crossref","unstructured":"Bisno AL, Gerber MA, Gwaltney JM Jr, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis.\u20082002;35:113\u2013125","DOI":"10.1086\/340949"},{"key":"2021120819510945400_R3","doi-asserted-by":"crossref","unstructured":"Pichichero ME. Group A streptococcal tonsillopharyngitis: cost-effective diagnosis and treatment. Ann Emerg Med.\u20081995;25:390\u2013403","DOI":"10.1016\/S0196-0644(95)70300-4"},{"key":"2021120819510945400_R4","unstructured":"Pichichero ME. Controversies in the treatment of streptococcal pharyngitis. Am Fam Physician.\u20081990;42:1567\u20131576"},{"key":"2021120819510945400_R5","doi-asserted-by":"crossref","unstructured":"Stillerman M. Comparison of oral cephalosporins with penicillin therapy for group A streptococcal pharyngitis. Pediatr Infect Dis.\u20081986;5:649\u2013654","DOI":"10.1097\/00006454-198611000-00010"},{"key":"2021120819510945400_R6","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Green JL, Francis AB, et al. Recurrent group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J.\u20081998;17:809\u2013815","DOI":"10.1097\/00006454-199809000-00012"},{"key":"2021120819510945400_R7","unstructured":"Brook I. Penicillin failure and copathogenicity in streptococcal pharyngotonsillitis. J Fam Pract.\u20081994;38:175\u2013179"},{"key":"2021120819510945400_R8","doi-asserted-by":"crossref","unstructured":"Brook I, Gober AE. Persistence of group A beta-hemolytic streptococci in toothbrushes and removable orthodontic appliances following treatment of pharyngotonsillitis. Arch Otolaryngol Head Neck Surg.\u20081998;124:993\u2013995","DOI":"10.1001\/archotol.124.9.993"},{"key":"2021120819510945400_R9","doi-asserted-by":"crossref","unstructured":"Kim KS, Kaplan EL. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr.\u20081985;107:681\u2013684","DOI":"10.1016\/S0022-3476(85)80392-9"},{"key":"2021120819510945400_R10","doi-asserted-by":"crossref","unstructured":"Bronze MS, Dale JB. The reemergence of serious group A streptococcal infections and acute rheumatic fever. Am J Med Sci.\u20081996;311:41\u201354","DOI":"10.1016\/S0002-9629(15)41630-1"},{"key":"2021120819510945400_R11","doi-asserted-by":"crossref","unstructured":"Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med.\u20081989;321:1\u20137","DOI":"10.1056\/NEJM198907063210101"},{"key":"2021120819510945400_R12","doi-asserted-by":"crossref","unstructured":"Johnson DR, Wotton JT, Shet A, et al. A comparison of group A streptococci from invasive and uncomplicated infections: are virulent clones responsible for serious streptococcal infections?J Infect Dis.\u20082002;185:1586\u20131595","DOI":"10.1086\/340576"},{"key":"2021120819510945400_R13","doi-asserted-by":"crossref","unstructured":"Pichichero ME, Hoeger W, Marsocci SM, et al. Variables influencing penicillin treatment outcome in streptococcal tonsillopharyngitis. Arch Pediatr Adolesc Med.\u20081999;153:565\u2013570","DOI":"10.1001\/archpedi.153.6.565"},{"key":"2021120819510945400_R14","doi-asserted-by":"crossref","unstructured":"el-Daher NT, Hijazi SS, Rawashdeh NM, et al. Immediate vs. delayed treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin V. Pediatr Infect Dis J.\u20081991;10:126\u2013130","DOI":"10.1097\/00006454-199102000-00010"},{"key":"2021120819510945400_R15","unstructured":"ROCEPHIN (ceftriaxone sodium) for Injection Prescribing Information. Hoffman-La Roche; 1998. Available at: www.rocheusa.com\/products\/rocephin\/pi.html"},{"key":"2021120819510945400_R16","doi-asserted-by":"crossref","unstructured":"Cohen R, Navel M, Grunberg J, et al. One dose ceftriaxone vs. ten days of amoxicillin\/clavulanate therapy for acute otitis media: clinical efficacy and change in nasopharyngeal flora. Pediatr Infect Dis J.\u20081999;18:403\u2013409","DOI":"10.1097\/00006454-199905000-00002"},{"key":"2021120819510945400_R17","doi-asserted-by":"crossref","unstructured":"Handsfield HH, Hook EW 3rd. Ceftriaxone for treatment of uncomplicated gonorrhea: routine use of a single 125-mg dose in a sexually transmitted disease clinic. Sex Transm Dis\u20081987;14:227\u2013230","DOI":"10.1097\/00007435-198710000-00010"},{"key":"2021120819510945400_R18","doi-asserted-by":"crossref","unstructured":"Kaplan EL, Johnson DR. Unexplained reduced microbiological efficacy of intramuscular benzathine penicillin G and of oral penicillin V in eradication of group a streptococci from children with acute pharyngitis. Pediatrics.\u20082001;108:1180\u20131186","DOI":"10.1542\/peds.108.5.1180"},{"key":"2021120819510945400_R19","doi-asserted-by":"crossref","unstructured":"Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther.\u20081979;26:294\u2013305","DOI":"10.1002\/cpt1979263294"},{"key":"2021120819510945400_R20","doi-asserted-by":"crossref","unstructured":"Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci.\u20081982;71:1344\u20131348","DOI":"10.1002\/jps.2600711209"},{"key":"2021120819510945400_R21","doi-asserted-by":"crossref","unstructured":"Jelliffe R, Bayard D, Milman M, et al. Achieving target goals most precisely using nonparametric compartmental models and \u201cmultiple model\u201d design of dosage regimens. Ther Drug Monit.\u20082000;22:346\u2013353","DOI":"10.1097\/00007691-200006000-00018"},{"key":"2021120819510945400_R22","doi-asserted-by":"crossref","unstructured":"D'Argenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed.\u20081979;9:115\u2013134","DOI":"10.1016\/0010-468X(79)90025-4"},{"key":"2021120819510945400_R23","doi-asserted-by":"crossref","unstructured":"Cellesi C, Chigiotti S, Zanchi A, et al. Susceptibility of macrolide and beta-lactam antibiotics of Streptococcus pyogenes strains isolated over a four-year period in central Italy. J Chemother.\u20081996;8:188\u2013192","DOI":"10.1179\/joc.1996.8.3.188"},{"key":"2021120819510945400_R24","doi-asserted-by":"crossref","unstructured":"Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet.\u20081989;17:223\u2013235","DOI":"10.2165\/00003088-198917040-00002"},{"key":"2021120819510945400_R25","doi-asserted-by":"crossref","unstructured":"Leibovitz E, Piglansky L, Raiz S, Press J, Leiberman A, Dagan R. Bacteriologic and clinical efficacy of one day vs three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J.\u20082000;19:1040\u20131045","DOI":"10.1097\/00006454-200011000-00003"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/4\/927\/1024260\/zpe01005000927.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/4\/927\/1024260\/zpe01005000927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T22:57:03Z","timestamp":1639004223000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/116\/4\/927\/68114\/Explaining-the-Poor-Bacteriologic-Eradication-Rate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,10,1]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2294","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10,1]]}}}